Aimed Bio Inc. (KOSDAQ:0009K0)
South Korea · Delayed Price · Currency is KRW 27,050
-400 (-1.46%)
At close: Aug 13, 2026
Aimed Bio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| 66,789 | 47,278 | 11,760 | 171.21 | 111.09 | |
Revenue Growth | 222.57% | 302.02% | 6768.70% | 54.12% | - |
Gross Profit | 66,789 | 47,278 | 11,760 | 171.21 | 111.09 |
Selling, General & Admin | 40,325 | 25,128 | 10,704 | 5,529 | 4,922 |
Amortization of Goodwill & Intangibles | 303.38 | 294.32 | 120.25 | 64.32 | 49.76 |
Operating Expenses | 42,571 | 26,510 | 12,168 | 6,588 | 5,703 |
Operating Income | 24,218 | 20,769 | -407.75 | -6,416 | -5,592 |
Interest Expense | -139.12 | -57.03 | -93.11 | -119.08 | -123.26 |
Interest & Investment Income | 3,806 | 1,840 | 1,117 | 207.22 | 162.72 |
Currency Exchange Gain (Loss) | 1,984 | -736.71 | 89.94 | 7.27 | 60.6 |
Other Non Operating Income (Expenses) | -239.07 | -25,646 | -4,116 | -1,617 | 11.45 |
EBT Excluding Unusual Items | 29,629 | -3,831 | -3,411 | -7,938 | -5,480 |
Gain (Loss) on Sale of Investments | -1,227 | -317.63 | 96.75 | -1,084 | -716.25 |
Gain (Loss) on Sale of Assets | -20.3 | -16.22 | 0.66 | -7.24 | -12.95 |
Pretax Income | 28,383 | -4,164 | -3,313 | -9,030 | -6,210 |
Income Tax Expense | -10,211 | -9,183 | - | - | - |
Earnings From Continuing Operations | 38,594 | 5,018 | -3,313 | -9,030 | -6,210 |
Minority Interest in Earnings | 2.6 | 4.48 | 9.28 | 6.95 | 41.03 |
Net Income | 38,596 | 5,023 | -3,304 | -9,023 | -6,168 |
Net Income to Common | 38,596 | 5,023 | -3,304 | -9,023 | -6,168 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 61 | 46 | 36 | 34 | 33 |
Shares Outstanding (Diluted) | 66 | 50 | 36 | 34 | 33 |
Shares Change | 83.25% | 39.67% | 4.02% | 2.16% | - |
EPS (Basic) | 633.60 | 108.11 | -93.00 | -264.18 | -184.51 |
EPS (Diluted) | 588.54 | 101.00 | -93.00 | -264.18 | -184.51 |
EPS Growth | - | - | - | - | - |
Free Cash Flow | 9,614 | 17,506 | -5,098 | -3,440 | -4,360 |
Free Cash Flow Per Share | 146.64 | 352.83 | -143.49 | -100.72 | -130.42 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | 36.26% | 43.93% | -3.47% | -3747.54% | -5033.36% |
Profit Margin | 57.79% | 10.62% | -28.09% | -5269.87% | -5552.44% |
Free Cash Flow Margin | 14.39% | 37.03% | -43.35% | -2009.11% | -3924.65% |
EBITDA | 25,825 | 22,151 | 1,056 | -5,358 | -4,811 |
EBITDA Margin | 38.67% | 46.85% | 8.98% | - | - |
D&A For EBITDA | 1,608 | 1,382 | 1,464 | 1,058 | 780.45 |
EBIT | 24,218 | 20,769 | -407.75 | -6,416 | -5,592 |
EBIT Margin | 36.26% | 43.93% | -3.47% | - | - |